scholarly journals Age features of metabolic syndrome and cardiovascular disorders in gout

2012 ◽  
Vol 14 (S1) ◽  
Author(s):  
Surayo Shukurova ◽  
Khisrav Toirov ◽  
Nabijon Hamidov ◽  
Dilfuza Jonnazarova
Keyword(s):  
Metabolic Syndrome ◽  
Cardiovascular Disorders ◽  
Age Features

scholarly journals Age features of metabolic syndrome effects on fetal embryonic development of the male rat offsprings

2016 ◽  
Vol 21 (2) ◽  
pp. 71-75
Author(s):  
O. Tkachenko ◽  
V. Kovalenko
Keyword(s):  
Metabolic Syndrome ◽  
Embryonic Development ◽  
Comparative Study ◽  
Fetal Death ◽  
Total Mortality ◽  
Male Rats ◽  
Male Rat ◽  
Adult Rats ◽  
Juvenile Age ◽  
Age Features

Comparative study of embryo-fetal death in females fertilized by males with metabolic syndrome, induced in adult or juvenile age has shown that the offspring of adult rats did not have significant abnormalities in embrio- and fetogenesis. At the same time it has been revealed 4% postimplantation death of offspring in male rats with metabolic syndrome induced in the juvenile age. The pre-implantation loss in this group was 6 folds higher than in control. Accordingly, the total mortality of the offspring rose 2.4 times in comparison with control.

scholarly journals The Pathophysiology of HIV-/HAART-Related Metabolic Syndrome Leading to Cardiovascular Disorders: The Emerging Role of Adipokines

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
John Palios ◽  
Nikolaos P. E. Kadoglou ◽  
Stylianos Lampropoulos
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Highly Active Antiretroviral Therapy ◽  
Cardiovascular Complications ◽  
Cardiovascular Disorders ◽  
Highly Active ◽  
Arterial Blood ◽  
Immunodeficiency Virus

Individuals infected with human immunodeficiency virus (HIV) frequently demonstrate metabolic syndrome (MS) associated with increased incidence of cardiovascular disorders. Characteristics of HIV infection, such as immunodeficiency, viral load, and duration of the disease, in addition to the highly active antiretroviral therapy (HAART) have been suggested to induce MS in these patients. It is well documented that MS involves a number of traditional cardiovascular risk factors, like glucose, lipids, and arterial blood pressure abnormalities, leading to extensive atherogenic arterial wall changes. Nevertheless, the above traditional cardiovascular risk factors merely explain the exacerbated cardiovascular risk in MS. Nowadays, the adipose-tissue derivatives, known as adipokines, have been suggested to contribute to chronic inflammation and the MS-related cardiovascular disease. In view of a novel understanding on how adipokines affect the pathogenesis of HIV/HAART-related MS and cardiovascular complications, this paper focuses on the interaction of the metabolic pathways and the potential cardiovascular consequences. Based on the current literature, we suggest adipokines to have a role in the pathogenesis of the HIV/HAART-related MS. It is crucial to understand the pathophysiology of the HIV/HAART-related MS and apply therapeutic strategies in order to reduce cardiovascular risk in HIV patients.

scholarly journals Stress in Obesity and Associated Metabolic and Cardiovascular Disorders

Scientifica ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-19 ◽  
Author(s):  
Paul Holvoet
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Molecular Mechanisms ◽  
Chronic Inflammatory Disease ◽  
Stress Conditions ◽  
Cardiovascular Disorders ◽  
Control Mechanisms ◽  
Complex Disorder ◽  
The Metabolic Syndrome

Obesity has significant implications for healthcare, since it is a major risk factor for both type 2 diabetes and the metabolic syndrome. This syndrome is a common and complex disorder combining obesity, dyslipidemia, hypertension, and insulin resistance. It is associated with high atherosclerotic cardiovascular risk, which can only partially be explained by its components. Therefore, to explain how obesity contributes to the development of metabolic and cardiovascular disorders, more and better insight is required into the effects of personal and environmental stress on disease processes. In this paper, we show that obesity is a chronic inflammatory disease, which has many molecular mechanisms in common with atherosclerosis. Furthermore, we focus on the role of oxidative stress associated with obesity in the development of the metabolic syndrome. We discuss how several stress conditions are related to inflammation and oxidative stress in association with obesity and its complications. We also emphasize the relation between stress conditions and the deregulation of epigenetic control mechanisms by means of microRNAs and show how this impairment further contributes to the development of obesity, closing the vicious circle. Finally, we discuss the limitations of current anti-inflammation and antioxidant therapy to treat obesity.

scholarly journals Association of S100B Serum Levels with Metabolic Syndrome and its Components

2018 ◽  
Vol 31 (4) ◽  
pp. 201 ◽  
Author(s):  
Sorayya Kheirouri ◽  
Elham Ebrahimi ◽  
Mohammad Alizadeh
Keyword(s):  
Metabolic Syndrome ◽  
Abdominal Obesity ◽  
Healthy Subjects ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Serum Levels ◽  
S100b Protein ◽  
Control Group ◽  
Cardiovascular Disorders

Introduction: We aimed to compare serum levels of S100B between patients with metabolic syndrome and healthy subjects and to investigate the association of S100B with components of the metabolic syndrome.Materials and Methods: In this study, 44 patients with metabolic syndrome and 44 healthy subjects participated. The participants’ body mass index, waist circumference, systolic and diastolic blood pressure were measured. Serum levels of low and high density lipoprotein cholesterol, total cholesterol, triglyceride, fasting blood glucose, insulin, S100B protein were determined by enzymatic and ELISA methods.Results: The participants with metabolic syndrome had significantly higher levels of S100B than those in the control group (p < 0.0001). Serum levels of S100B protein were positively correlated with abdominal obesity (rho = 0.26; p = 0.01) and serum levels of triglyceride (rho = 0.26; p = 0.01). Moreover, serum levels of S100B were higher in subjects with abdominal obesity (p = 0.02), with higher serum triglyceride levels (p = 0.03) and with hypertension (p = 0.01).Conclusion: The findings indicate that there may be a link between S100B protein with abdominal obesity and serum levels of triglycerides. This warrants further research to elucidate whether increased S100B levels in patients with metabolic syndrome are involved in the pathogenesis of cardiovascular disorders.

scholarly journals Main Features of Impaired Fibronolytic and Protolytic Activity of Blood Plasma in Patients with Osteoarthritis Depending on Comorbidity

2016 ◽  
Vol 23 (4) ◽  
pp. 2016417
Author(s):  
Larysa Voloshyna
Keyword(s):  
Metabolic Syndrome ◽  
Cardiovascular Risk ◽  
Blood Plasma ◽  
Cardiovascular System ◽  
Proteolytic Activity ◽  
Blood Levels ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Age Features ◽  
High Comorbidity

The objective of the research was to study the features of impaired fibrinolytic and proteolytic activity of blood plasma in patients with osteoarthritis (OA), depending on the age levels of comorbidity.Material and methods. The age features of comorbid processes prevalence in 120 patients with OA were clinically studied, fibrinolytic and proteolytic activity of blood, levels of fibrinogen and C-reactive protein were also studied using biochemical methods.Results. Comorbidity in patients with OA at the age under 50 was established low. The level of comorbidity increases to at the age of 51-60, after 60 years the phenomenon of comorbidity is more significant by frequency and severity. The diseases of the cardiovascular system dominated, including metabolic syndrome, diseases of the digestive tract and kidneys were less frequent. Cardiovascular risk (CVR) levels were high after the age of 50, gastrointestinal risk was less frequent. Fibrinolysis minor disorders were observed in patients with low comorbidity, namely fibrinolytic and proteolytic activity of blood as a part of high CVR progressively deteriorated and the level of fibrinogen and C-reactive protein increased in the patients at the age after 50 (especially 60) on the background of high comorbidity levels. Conclusions. The level of comorbidity and CVR increased in patients with OA with age, increase in disease severity and duration. These phenomena were accompanied by progressive disorders in fibrinolytic and proteolytic activity of the blood, increased levels of fibrinogen and C-reactive protein as one of the components of CVR.

AGE FEATURES OF COLLAGEN EXCHANGE MARKERS IN PATIENTS WITH HEART FAILURE WITH INTERMEDIATE EMISSION FACTION ON THE BACKGROUND OF METABOLIC SYNDROME

Vrach ◽  
2020 ◽  
Vol 31 (6) ◽  
Author(s):  
Osipova O.A. ◽  
Drapkina O.M. ◽  
Shepel' R.N. ◽  
Gosteva E.V. ◽  
Godlevskaja O.M. ◽  
...  
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Patients With Heart Failure ◽  
Age Features

scholarly journals The Role of Selenium in Health and Disease: Emerging and Recurring Trends

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1049 ◽  
Author(s):  
Catherine Méplan ◽  
David J. Hughes
Keyword(s):  
Metabolic Syndrome ◽  
Viral Infection ◽  
Disease Risk ◽  
Research Articles ◽  
Original Research ◽  
Cardiovascular Disorders ◽  
Special Issue ◽  
Health And Disease ◽  
Potential Biomarkers

In this Special Issue of Nutrients, “The Role of Selenium in Health and Disease” covers diverse diseases in the 8 original research articles and 2 reviews, such as cardiovascular disorders (CVD), metabolic syndrome, obesity, cancer, and viral infection, and highlights novel potential biomarkers of disease risk and prognosis [...]

Comorbidities in the first 2 years after arthroscopic hip surgery: substantial increases in mental health disorders, chronic pain, substance abuse and cardiometabolic conditions

2018 ◽  
Vol 53 (9) ◽  
pp. 547-553 ◽  
Author(s):  
Daniel I Rhon ◽  
Tina A Greenlee ◽  
Bryant G Marchant ◽  
Charles Dennis Sissel ◽  
Chad E Cook
Keyword(s):  
Mental Health ◽  
Metabolic Syndrome ◽  
Substance Abuse ◽  
Chronic Pain ◽  
Sleep Disorders ◽  
Mental Health Disorders ◽  
Hip Surgery ◽  
Cardiovascular Disorders ◽  
Substance Abuse Disorders ◽  
Health Disorders

ObjectivesWe aimed to identify the rate of seven comorbidities (mental health disorders, chronic pain, substance abuse disorders, cardiovascular disorders, metabolic syndrome, systemic arthropathy and sleep disorders) that occurred within 2 years after hip arthroscopy.MethodsData from individuals (ages 18–50 years) undergoing arthroscopic hip surgery between 2004 and 2013 were collected from the Military Health System (MHS) Data Repository (MDR). The MDR captures all healthcare encounters in all settings and locations for individuals within the MHS. Person-level data over 36 months were pulled and aggregated. Seven comorbidities related to poor outcomes from musculoskeletal disorders (mental health disorders, chronic pain, substance abuse disorders, cardiovascular disorders, metabolic syndrome, systemic arthropathy and sleep disorders) were examined 12 months prior and 24 months after surgery. Changes in frequencies were calculated as were differences in proportions between presurgery and postsurgery.Results1870 subjects were identified (mean age 32.24 years; 55.5% men) and analysed. There were statistically significant increases (p<0.001) proportionally for all comorbidities after surgery. Relative to baseline, cases of mental health disorders rose 84%, chronic pain diagnoses increased 166%, substance abuse disorders rose 57%, cardiovascular disorders rose by 71%, metabolic syndrome cases rose 85.9%, systemic arthropathy rose 132% and sleep disorders rose 111%.ConclusionsMajor (potentially ‘hidden’) clinical comorbidities increased substantially after elective arthroscopic hip surgery when compared with preoperative status. These comorbidities appear to have been overlooked in major studies evaluating the benefits and risks of arthroscopic hip surgery.Level of evidencePrognostic, level III.

Sign in / Sign up

Export Citation Format

Share Document